| Market Cap | 11.9B |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | 0.05 |
| Dividend Yield | - |
| D/E Ratio | 0.94 |
| Current Ratio | 1.52 |
| Market Segment | STAR Market |
| Currency | CNY |
Business Overview
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | Pharmaceutical Manufacturing |
| Market Segment | STAR Market |
| Currency | CNY |
| Fiscal Year | 2024 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | 欧林生物 |
| Ticker | 688319 |
| Exchange | SSE |
| Sector | CSRC Classification |
| Industry | Pharmaceutical Manufacturing |
| Market Segment | STAR Market |
| Fiscal Year | 2024 |
| Currency | CNY |
| Market Cap | 11.9B |
| Revenue | 589.0M |
| Net Income | 15.7M |
| P/E Ratio | - |
| EPS | 0.05 |
| Net Margin | 2.7% |
| ROE | 1.7% |
| Dividend Yield | - |
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.